arrow Log In to View Account     |      
HOME
Johns Hopkins Medicine
Hopkins Logo


Disclaimer: CME certification for these activities has expired. All information is pertinent to the timeframe in which it was released.


Clinical and Economic Factors of Combination Therapy in Asthma


GOAL
To provide physicians and pharmacists with practical information for assessing the clinical and economic factors of dual-controller therapies for asthma management.

TARGET AUDIENCE
This activity is designed for pulmonologists, allergists, immunologists, primary care physicians, and pharmacists who manage and treat patients with asthma.

LEARNING OBJECTIVES
National Heart, Lung, and Blood Institute (NHLBI) guidelines for asthma management recommend that anti-inflammatory medications be the foundation of pharmacotherapy for persistent asthma in view of the importance of inflammation in asthma pathophysiology. For moderate or severe persistent asthma, dual-controller regimens (ie, combinations of two or more therapies with complementary mechanisms of action) are advised. The past decade has seen an explosion of research on dual-controller options for asthma therapy. This slide set discusses the sources of information that health care providers should consider in choosing among dual-controller regimens and reviews the newest data on the dual-controller options. Upon completion of this program, participants will be able to:

  • Consider the empirical sources of information health care providers should use in evaluating the relative value of pharmacotherapies;
  • Understand the strengths and weaknesses of randomized, controlled clinical trials versus observational studies;
  • Become familiar with data from randomized, controlled clinical trials of a new dual-controller regimen for asthma; and
  • Become familiar with clinical data from observational studies of a new dual-controller regimen for asthma.

ACCREDITATION STATEMENT
This activity has been planned and produced in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education. The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The Johns Hopkins School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

CREDIT DESIGNATION STATEMENT
The Johns Hopkins University School of Medicine designates this continuing medical education activity for a maximum of 1 hour in category 1 credit toward the American Medical Association Physicians' Recognition Award. Each physician should claim only those hours of credit that are actually spent on the educational activity. Credits are available until the expiration date of January 31, 2004.

This continuing education activity was produced under the supervision of Peter S. Creticos, MD, Associate Professor of Medicine, Johns Hopkins University School of Medicine, Clinical Director, Division of Allergy and Clinical Immunology; and Medical Director, Asthma and Allergy Diseases, Johns Hopkins Asthma & Allergy Center.

This program is approved for 1 hour of credit (0.1 CEUs) and is co-sponsored with the University of Tennessee College of Pharmacy, which is approved by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education. ACPE Program #064-999-02-211-H01.

This program is supported by an unrestricted educational grant from GlaxoSmithKline.

FULL DISCLOSURE POLICY AFFECTING CME ACTIVITIES

FACULTY MEMBER
Peter S. Creticos, MD, reports grant/research support from, serving as a consultant to, and is a member of the speakers' bureau for ALK, Allergenics, Aradigon, Aventis, AstraZeneca, Dynarax, GlaxoSmithKline, Janssen, McNeil, Merck, Pfizer, Pharmacia & Upjohn, Schering-Plough, and Stallergens.

Michael S. Blaiss, MD, reports receiving honoraria from, serving as a consultant to, and is a shareholder for GlaxoSmithKline, Merck, and Aventis.

Richard D. O'Connor, MD, reports serving as a consultant to Health Benchmarks Inc. and on the speakers' bureau for GlaxoSmithKline, Aventis, Pfizer, Shering, and Pharmacia, and is a shareholder for Elan, GlaxoSmithKline, and Forest.

Samy Suissa, PhD, reports receiving grant/research support from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, and Schering-Plough; and serving as a consultant to Organon.

PUBLISHER'S NOTE AND DISCLAIMER
The opinions expressed in this issue are those of the authors, presenters, and/or panelists and are not attributable to the publisher, editor, advisory board of Advanced Studies in Medicine, or The Johns Hopkins University School of Medicine or its Office of Continuing Medical Education. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this issue are not necessarily the same as indicated in the package insert for the product and may reflect the clinical experience of the authors, presenters, and/or panelists or may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Advanced Studies in Medicine (ISSN-1530-3004) is published by Galen Publishing, LLC, an HMG Company. P.O. Box 340, Somerville, NJ 08876. (908) 253-9001. Web site: www.galenpublishing.com. Copyright ©2001 by Galen Publishing, LLC. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. Bulk postage paid at Somerville, NJ Post Office and at additional mailing offices. Advanced Studies in Medicine is a registered trademark of The Healthcare Media Group, LLC. Printed on acid-free paper. BPA Membership applied for December 2000.

CHAIRPERSON

    Peter S. Creticos, MD
    Associate Professor of Medicine
    Johns Hopkins University School of Medicine
    Clinical Director, Division of Allergy and Clinical Immunology
    Medical Director, Asthma and Allergy Diseases
    Johns Hopkins Asthma and Allergy Center
    Baltimore, Maryland

FACULTY

    Michael S. Blaiss, MD
    Clinical Professor of Pediatrics and Medicine
    University of Tennessee Center of Health Sciences College of Medicine
    Cordova, Tennessee

    Richard D. O'Connor, MD
    Clinical Professor of Pediatrics
    University of California, San Diego
    Director of Quality Management
    Sharp Rees-Stealy Medical Centers
    Division of Asthma, Allergy, and Clinical Immunology
    San Diego, California

    Samy Suissa, PhD
    Director, Division of Clinical Epidemiology
    McGill University Health Center
    Royal Victoria Hospital
    Montreal, Canada

Advanced Studies in Medicine provides disclosure information from contributing authors, participating faculty, and presenters only. Advanced Studies in Medicine does not provide disclosure information from authors of abstracts and poster presentations. The reader shall be advised that these contributors may or may not maintain financial relationships with pharmaceutical companies.

April 2002


Dear Colleague:

On behalf of The Johns Hopkins University School of Medicine, we are pleased to present you with this continuing education program titled "Clinical and Economic Factors of Combination Therapy in Asthma." This CD ROM Slide Lecture was developed to bring you new information about dual-controller therapy, the treatment strategy recommended by the National Heart, Lung, and Blood Institute for persistent asthma. The slide lecture is accompanied by expert commentary that will help you disseminate this information to other health care providers involved in the management of patients with asthma.

The CD ROM Slide Lecture considers the newest data on dual-controller therapy for asthma management in the context of the two primary sources of empirical evidence for evaluating pharmacotherapies-ie, randomized, controlled clinical trials and observational studies. The CD ROM Slide Lecture also reviews the complementary features of randomized, controlled clinical trials and observational studies and then considers the clinical trials-based and clinical practice-based data useful for choosing among dual-controller regimens. We hope that you find the information helpful in improving your ability to provide quality care to patients with asthma.


Sincerely,

Peter S. Creticos, MD
Johns Hopkins University School of Medicine
Clinical Director, Division of Allergy and Clinical Immunology
Medical Director, Asthma and Allergy Diseases
Johns Hopkins Asthma & Allergy Center





Johns Hopkins Advanced Studies in Medicine (ISSN-1558-0334), is published by Galen Publishing, LLC, d/b/a ASiM, PO Box 340, Somerville, NJ 08876. (908) 253-9001. Copyright ©2012 by Galen Publishing. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of The Healthcare Media Group, LLC.